Yu Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu Zhou has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoyu Li
Department of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong SAR, China
4 shared publications - Yan Cao
Department of Biochemical Pharmacy, School of Pharmacy, Naval Medical University, Shanghai 200433, China; Shanghai Key Laboratory for Pharmaceutical Metabolite Research, School of Pharmacy, Naval Medical University, Shanghai 200433, China
3 shared publications Jianzhao Peng
Department of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong SAR, China
2 shared publicationsWenyin Shen
Department of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong SAR, China
2 shared publicationsYiran Huang
Department of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Pokfulam Road, Hong Kong SAR 999077, China
2 shared publications- Yizhou Li
Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University, Chongqing, China
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5704-5717
A γ-AApeptide-Based Antibody-like Peptidomimetic for Enhanced EGFR-Targeted PET Imaging
Targeted imaging for the extracellular domain (ECD) of epidermal growth factor receptor (EGFR) is promising for early diagnosis and therapeutic applications toward cancers. Herein, we report the design of a γ-AApeptide-based antibody-like peptidomimetic as a radiotracer for EGFR-targeted positron emission tomography (PET) imaging. A dimeric cyclic γ-AApeptide (D1) was designed by dimerizing a previously reported EGFR-binding peptidomimetic ligand, resulting in a 6-fold enhancement in binding affinity (Kd = 0.11 μM) compared to its monomeric counterpart (M1, Kd = 0.67 μM). Both ligands were conjugated with chelators and radiolabeled with 64Cu to yield [64Cu]Cu-NOTA-M1 (monomer) and [64Cu]Cu-DOTA-D1 (dimer), respectively. In vivo PET imaging demonstrated that [64Cu]Cu-DOTA-D1 achieved significantly higher tumor uptake than [64Cu]Cu-NOTA-M1 in EGFR-positive tumor models (e.g., 10.83 ± 2.70 %ID/g vs 2.80 ± 0.72 %ID/g in U87 tumors at 4 h p.i.). Blocking and EGFR-negative control studies further confirmed the targeting specificity of [64Cu]Cu-DOTA-D1. Ex vivo biodistribution analysis showed consistent enhancement in tumor uptake (e.g., 7.94 ± 0.24 %ID/g vs 3.81 ± 0.44 %ID/g in U87 tumors at 48 h p.i.) for the dimeric tracer, accompanied by increased uptake in clearance organs. Overall, this work demonstrates that cyclic γ-AApeptides could serve as effective antibody-like peptidomimetics for EGFR targeting in vivo and provides a versatile strategy for developing peptidomimetic radiotracers for molecular imaging applications.
- 29 September 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5704-5717
Open AccessA γ-AApeptide-Based Antibody-like Peptidomimetic for Enhanced EGFR-Targeted PET Imaging
Targeted imaging for the extracellular domain (ECD) of epidermal growth factor receptor (EGFR) is promising for early diagnosis and therapeutic applications toward cancers. Herein, we report the design of a γ-AApeptide-based antibody-like peptidomimetic as a radiotracer for EGFR-targeted positron emission tomography (PET) imaging. A dimeric cyclic γ-AApeptide (D1) was designed by dimerizing a previously reported EGFR-binding peptidomimetic ligand, resulting in a 6-fold enhancement in binding affinity (Kd = 0.11 μM) compared to its monomeric counterpart (M1, Kd = 0.67 μM). Both ligands were conjugated with chelators and radiolabeled with 64Cu to yield [64Cu]Cu-NOTA-M1 (monomer) and [64Cu]Cu-DOTA-D1 (dimer), respectively. In vivo PET imaging demonstrated that [64Cu]Cu-DOTA-D1 achieved significantly higher tumor uptake than [64Cu]Cu-NOTA-M1 in EGFR-positive tumor models (e.g., 10.83 ± 2.70 %ID/g vs 2.80 ± 0.72 %ID/g in U87 tumors at 4 h p.i.). Blocking and EGFR-negative control studies further confirmed the targeting specificity of [64Cu]Cu-DOTA-D1. Ex vivo biodistribution analysis showed consistent enhancement in tumor uptake (e.g., 7.94 ± 0.24 %ID/g vs 3.81 ± 0.44 %ID/g in U87 tumors at 48 h p.i.) for the dimeric tracer, accompanied by increased uptake in clearance organs. Overall, this work demonstrates that cyclic γ-AApeptides could serve as effective antibody-like peptidomimetics for EGFR targeting in vivo and provides a versatile strategy for developing peptidomimetic radiotracers for molecular imaging applications.
- 22 August 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (35) , 24638-24653
Agonist Discovery for Membrane Proteins on Live Cells by Using DNA-encoded Libraries
Identifying biologically active ligands for membrane proteins is an important task in chemical biology. We report an approach to directly identify small molecule agonists against membrane proteins by selecting DNA-encoded libraries (DELs) on live cells. This method connects extracellular ligand binding with intracellular biochemical transformation, thereby biasing the selection toward agonist identification. We have demonstrated the methodology with three membrane proteins: epidermal growth factor receptor (EGFR), thrombopoietin receptor (TPOR), and insulin receptor (INSR). A ∼30 million and a 1.033 billion-compound DEL were selected against these targets, and novel agonists with subnanomolar affinity and low micromolar cellular activities have been discovered. The INSR agonists activated the receptor by possibly binding to an allosteric site, exhibited clear synergistic effects with insulin, and activated the downstream signaling pathways. Notably, the agonists did not activate the insulin-like growth factor 1 receptor (IGF-1R), a highly homologous receptor whose activation may lead to tumor progression. Collectively, this work has developed an approach toward "functional" DEL selections on the cell surface and may provide a widely applicable method for agonist discovery for membrane proteins.
- 22 August 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (35) , 24638-24653
Agonist Discovery for Membrane Proteins on Live Cells by Using DNA-encoded Libraries
Identifying biologically active ligands for membrane proteins is an important task in chemical biology. We report an approach to directly identify small molecule agonists against membrane proteins by selecting DNA-encoded libraries (DELs) on live cells. This method connects extracellular ligand binding with intracellular biochemical transformation, thereby biasing the selection toward agonist identification. We have demonstrated the methodology with three membrane proteins: epidermal growth factor receptor (EGFR), thrombopoietin receptor (TPOR), and insulin receptor (INSR). A ∼30 million and a 1.033 billion-compound DEL were selected against these targets, and novel agonists with subnanomolar affinity and low micromolar cellular activities have been discovered. The INSR agonists activated the receptor by possibly binding to an allosteric site, exhibited clear synergistic effects with insulin, and activated the downstream signaling pathways. Notably, the agonists did not activate the insulin-like growth factor 1 receptor (IGF-1R), a highly homologous receptor whose activation may lead to tumor progression. Collectively, this work has developed an approach toward "functional" DEL selections on the cell surface and may provide a widely applicable method for agonist discovery for membrane proteins.
- 7 February 2024
- Published by Springer Nature in Nature Chemistry
- Vol. 16 (4) , 543-555
Protein-templated ligand discovery via the selection of DNA-encoded dynamic libraries
DNA-encoded chemical libraries (DELs) have become a powerful technology platform in drug discovery. Dual-pharmacophore DELs display two sets of small molecules at the termini of DNA duplexes, thereby enabling the identification of synergistic binders against biological targets, and have been successfully applied in fragment-based ligand discovery and affinity maturation of known ligands. However, dual-pharmacophore DELs identify separate binders that require subsequent linking to obtain the full ligands, which is often challenging. Here we report a protein-templated DEL selection approach that can identify full ligand/inhibitor structures from DNA-encoded dynamic libraries (DEDLs) without the need for subsequent fragment linking. Our approach is based on dynamic DNA hybridization and target-templated in situ ligand synthesis, and it incorporates and encodes the linker structures in the library, along with the building blocks, to be sampled by the target protein. To demonstrate the performance of this method, 4.35-million- and 3.00-million-member DEDLs with different library architectures were prepared, and hit selection was achieved against four therapeutically relevant target proteins.
- 7 February 2024
- Published by Springer Nature in Nature Chemistry
- Vol. 16 (4) , 543-555
Protein-templated ligand discovery via the selection of DNA-encoded dynamic libraries
DNA-encoded chemical libraries (DELs) have become a powerful technology platform in drug discovery. Dual-pharmacophore DELs display two sets of small molecules at the termini of DNA duplexes, thereby enabling the identification of synergistic binders against biological targets, and have been successfully applied in fragment-based ligand discovery and affinity maturation of known ligands. However, dual-pharmacophore DELs identify separate binders that require subsequent linking to obtain the full ligands, which is often challenging. Here we report a protein-templated DEL selection approach that can identify full ligand/inhibitor structures from DNA-encoded dynamic libraries (DEDLs) without the need for subsequent fragment linking. Our approach is based on dynamic DNA hybridization and target-templated in situ ligand synthesis, and it incorporates and encodes the linker structures in the library, along with the building blocks, to be sampled by the target protein. To demonstrate the performance of this method, 4.35-million- and 3.00-million-member DEDLs with different library architectures were prepared, and hit selection was achieved against four therapeutically relevant target proteins.
- 1 January 2024
- Published by Georg Thieme Verlag KG
3.2.1.1 Encoding Using Double-Stranded DNA: A Headpiece-Based DNA Ligation Strategy
DNA-encoded chemical libraries (DELs) provide a powerful high-throughput screening platform that is used in both academia and industry. High-quality DELs lay the foundation for reliable DEL selection outcomes, and most pharmaceutical companies would prefer double-stranded DELs (dsDELs) because of their superior stability. Here, we summarize the experimental details for encoding a dsDEL, including the overall encoding strategy, synthetic chemistry of building-block addition, ligation strategies of code elongation, and quality control of the resulting libraries, exemplified with a 320-million-membered benzimidazole dsDEL from GlaxoSmithKline (GSK). We also briefly review the successful selection cases involving the presented libraries to highlight the great potential of dsDELs in drug discovery.
- 1 January 2024
- Published by Georg Thieme Verlag KG
3.2.1.1 Encoding Using Double-Stranded DNA: A Headpiece-Based DNA Ligation Strategy
DNA-encoded chemical libraries (DELs) provide a powerful high-throughput screening platform that is used in both academia and industry. High-quality DELs lay the foundation for reliable DEL selection outcomes, and most pharmaceutical companies would prefer double-stranded DELs (dsDELs) because of their superior stability. Here, we summarize the experimental details for encoding a dsDEL, including the overall encoding strategy, synthetic chemistry of building-block addition, ligation strategies of code elongation, and quality control of the resulting libraries, exemplified with a 320-million-membered benzimidazole dsDEL from GlaxoSmithKline (GSK). We also briefly review the successful selection cases involving the presented libraries to highlight the great potential of dsDELs in drug discovery.
- 1 September 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 45, 116328
Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library
- 1 September 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 45, 116328
Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library
- 21 December 2020
- Published by Springer Nature in Nature Chemistry
- Vol. 13 (1) , 77-88
Selection of DNA-encoded chemical libraries against endogenous membrane proteins on live cells
Membrane proteins on the cell surface perform a myriad of biological functions; however, ligand discovery for membrane proteins is highly challenging, because a natural cellular environment is often necessary to maintain protein structure and function. DNA-encoded chemical libraries (DELs) have emerged as a powerful technology for ligand discovery, but they are mainly limited to purified proteins. Here we report a method that can specifically label membrane proteins with a DNA tag, and thereby enable target-specific DEL selections against endogenous membrane proteins on live cells without overexpression or any other genetic manipulation. We demonstrate the generality and performance of this method by screening a 30.42-million-compound DEL against the folate receptor, carbonic anhydrase 12 and the epidermal growth factor receptor on live cells, and identify and validate a series of novel ligands for these targets. Given the high therapeutic significance of membrane proteins and their intractability to traditional high-throughput screening approaches, this method has the potential to facilitate membrane-protein-based drug discovery by harnessing the power of DEL.
- 21 December 2020
- Published by Springer Nature in Nature Chemistry
- Vol. 13 (1) , 77-88
Selection of DNA-encoded chemical libraries against endogenous membrane proteins on live cells
Membrane proteins on the cell surface perform a myriad of biological functions; however, ligand discovery for membrane proteins is highly challenging, because a natural cellular environment is often necessary to maintain protein structure and function. DNA-encoded chemical libraries (DELs) have emerged as a powerful technology for ligand discovery, but they are mainly limited to purified proteins. Here we report a method that can specifically label membrane proteins with a DNA tag, and thereby enable target-specific DEL selections against endogenous membrane proteins on live cells without overexpression or any other genetic manipulation. We demonstrate the generality and performance of this method by screening a 30.42-million-compound DEL against the folate receptor, carbonic anhydrase 12 and the epidermal growth factor receptor on live cells, and identify and validate a series of novel ligands for these targets. Given the high therapeutic significance of membrane proteins and their intractability to traditional high-throughput screening approaches, this method has the potential to facilitate membrane-protein-based drug discovery by harnessing the power of DEL.